Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-92 PET Imaging in Alzheimer's Disease
NCT04926272Phase 2Unknown
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Florbetapir in Alzheimer's disease (AD), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Standardized Uptake Value Ratio, Cerebrospinal Fluid Beta-Amyloid 42 and 4 more. Status: unknown.
02
Drugs
Florbetapir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04926272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926272.